SPONSOR
BeiGene
Total Trials
5
Recruiting
5
Phases
Phase 4, Phase 1, Phase 2, Phase 1, Phase 2
Conditions studied: Waldenström's MacroglobulinemiaWaldenstrom MacroglobulinemiaB-cell MalignancyNon-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenström MacroglobulinemiaMarginal Zone LymphomaFollicular LymphomaDLBCL Unclassifiable
BeiGene is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Waldenström's Macroglobulinemia, Waldenstrom Macroglobulinemia, B-cell Malignancy, Non-Hodgkin Lymphoma.
The trial portfolio spans Phase 4, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — BeiGene
How many clinical trials has BeiGene sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by BeiGene, of which 5 are actively recruiting participants. These trials cover conditions including Waldenström's Macroglobulinemia, Waldenstrom Macroglobulinemia, B-cell Malignancy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does BeiGene research focus on?
BeiGene clinical trials span Waldenström's Macroglobulinemia, Waldenstrom Macroglobulinemia, B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, and additional conditions. The research pipeline includes Phase 4, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a BeiGene clinical trial?
To participate in a BeiGene trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all BeiGene trials with current recruitment status updated daily.
Clinical Trials by BeiGene
NCT07169331 Phase 4
Recruiting
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Waldenström's Macroglobulinemia
NCT05640102
Recruiting
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Waldenstrom Macroglobulinemia
NCT05294731 Phase 1, Phase 2
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
B-cell Malignancy
NCT06342713 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Healthy Participants
NCT03736889 Phase 2
Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology